Wire · opportunities
Regeneron Reports Phase 2 PINNACLE Data Show Baloncibart Improved Heart Rate ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
Regeneron's investigational monoclonal antibody, baloncibart, showed significant improvement in heart rate response and symptoms for POTS patients in Phase 2 trials, with a Phase 3 trial planned for 2027. This represents a novel potential therapy for a condition currently lacking FDA-approved treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Nov 2026 and 13 Nov 2026.
◆ ◆ The Wire takeaway
Your biotech venture developing treatments for rare cardiovascular disorders now faces a new competitor advancing towards regulatory approval. Baloncibart’s progress opens a clear pathway for first-in-class therapies and reshapes patient treatment expectations.
◆ Coverage
2 sources · first reported 12 Nov 2026 · latest 13 Nov 2026
◆ Related on Wire
◆ Topics